Skip to main content

Table 3 PET majority, AD and mCERADSOT assessment by disease category

From: Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

Disease category Number Percent PETmaj abnormal # With coincident ADa # mCERADSOT abnormal
Alzheimer's Diseasea 66 (62%) 62 66 64
Lewy Body Diseaseb 29 (27%) 23 16 22
Cerebral Amyloid Angiopathyc 27 (25%) 23 24 25
Vasculard 21 (20%) 14 14 16
Arteriosclerosise 13 (12%) 9 9 11
Infarct 7 (7%) 3 2 3
Normal 6 (6%) 0 0 0
Ageing Changes 3 (3%) 0 0 0
TDP43 immunopositivef 3 (3%) 0 0 2
Tangle predominant dementia 2 (2%) 0 0 0
Progressive Supranuclear Palsy 2 (2%) 0 0 0
Atherosclerosis 2 (2%) 1 2 2
Frontotemporal Dementia 1 (1%) 0 0 0
Metastatic carcinoma 1 (1%) 1 1 1
Hydrocephalus 1 (1%) 1 1 1
Multiple system atrophy 1 (1%) 1 0 1
Neurofibrillary degeneration 1 (1%) 0 0 1
Parkinson's Disease 1 (1%) 0 0 0
  1. AD Alzheimer’s disease, mCERAD SOT standard of truth by modified Consortium to Establish a Registry for Alzheimer’s Disease criteria, N Number of subjects, PETmaj majority read of positron emission tomography images, SOT standard of truth
  2. All neuropathology diagnoses made blind to clinical data
  3. aIncludes intermediate or high likelihood by National Institute of Ageing-Reagan Institute criteria irrespective of dementia status
  4. bDiagnosed as dementia with Lewy bodies blinded to clinical data
  5. cDoes not include focal cerebral amyloid angiopathy
  6. dIncludes: multifocal infarcts, microinfarcts, cerebral vascular disease, vascular brain injury and vascular dementia
  7. eincludes arteriosclerosis and arteriolosclerosis
  8. fTDP43 immunopositivity was recorded at the site neuropathology laboratories, not as part of the diagnoses for the GE studies. This analysis was not performed on all subjects